Clinical Trials Logo

Gynecological Malignancies clinical trials

View clinical trials related to Gynecological Malignancies.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06151028 Recruiting - Bone Loss Clinical Trials

An Observational Study of Menopausal Symptom in Patients With Gynecological Malignancy After Oophorectomy

Start date: December 1, 2023
Phase:
Study type: Observational

Through long-term dynamic monitoring of gynecologic malignant tumor patients undergoing early menopause after ovaries resection in our center, we explored the changes in menopausal symptoms and bone health status of this population, and studied the effects of platinum combined chemotherapy drugs on menopausal symptoms and bone loss in gynecologic malignant tumor patients. To find the optimal time point and effective regimen for MHT in gynecologic malignancies undergoing surgical menopause, and to provide guidance for osteoporosis screening and prevention strategies in women with gynecologic cancer.

NCT ID: NCT06131450 Recruiting - Clinical trials for Gynecological Malignancies

A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies

Start date: February 29, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a single-arm, open, multicenter, non-randomized phase Ib/II clinical study evaluating the efficacy and safety of BL-M07D1 for injection in patients with HER2-expressing recurrent or metastatic gynecologic malignancies.

NCT ID: NCT05914974 Recruiting - Ovarian Cancer Clinical Trials

Immunotherapy-related CRP Kinetics in Metastatic Gynecological Malignancies

Start date: September 11, 2023
Phase:
Study type: Observational

ICK-Gyn is a prospective, multicentric, non-interventional investigator-initiated trial (IIT) that aims to investigate the prognostic value of CRP kinetics in advanced or metastatic gynecological malignancies under immune checkpoint inhibitor (ICI) therapy on the objective response rate (ORR), progression-free survival (PFS) and overall survival (OS).

NCT ID: NCT04905329 Recruiting - Breast Cancer Clinical Trials

A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations

Def_Special
Start date: April 28, 2020
Phase:
Study type: Observational

This study was designed to evaluate the efficacy and safety of Extimia® (INN - empegfilgrastim) in reducing the frequency, duration of neutropenia, the incidence of febrile neutropenia and infections caused by febrile neutropenia in patients with High and "Gray Zone" Risk Reccurrence Breast Cancer, Gastointestinal Cancers and Gynecological Malignancies